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 Microgravity conditions associated with space flight have been shown to 
cause immune deficiencies in a number of ways, such as decreasing hematopoietic 
differentiation, cytokine production, and lymphocyte proliferation1. Space flight has 
also been shown to cause changes in DNA fragmentation and changes in lymphoid 
organ size in mice models2. Research on immunology in spaceflight became a 
prevalent topic when NASA published results of a significantly high re-emergence of 
latent viruses in astronauts returning from space missions, with additional studies 
showing decreases in cytokine activation and virus-specific T cells3, 4. The evidence 
for immune system impairment in microgravity conditions is particularly 
concerning given the plans for longer duration spaceflights for humans. Further 
research needs to be conducted to better understand the effect of microgravity on 
immune function. This proposed experiment will investigate the effect of 
microgravity on adaptive immune response to viral infection by inoculating mice 
with a virus and studying the immune responses of mice in simulated microgravity 
conditions. It is hypothesized that the mice in the simulated microgravity condition 
will show a lower antibody response to LCMV than the control group. Data will be 
obtained through the use of plaque assays, intracellular cytokine staining, tetramer 
staining, and ELISAs. Based on previous findings, is anticipated that the hypothesis 
will be supported; however, aberrant results would still provide insight to the role 




The first landing on the moon was in 1969, and NASA proposes to have 
humans land on Mars by 2030. Outer space is an exciting scientific frontier to 
explore, but the factors associated with spaceflights of any duration can lead to 
significant impairment of health. Unsurprisingly, leaving the earth’s orbit brings 
about a number of unfamiliar circumstances to the individuals who venture out of 
the atmosphere. The rocket’s takeoff results in a massive exposure to G forces, and 
the missions themselves tend to result in severe sleep deprivation, nutritional 
deficiencies, and anxiety or depression1. In addition, research shows that the 
immune system suffers from the microgravity conditions experienced.  
 Microgravity refers to conditions where the force of gravity is so low that 
feelings of weightlessness occur. Gravity is generally measured by the speed at 
which an object would fall in free fall. On Earth, gravity is 9.807m/s2. This value 
significantly decreases once Earth’s atmosphere is exited—on Mars the force of 
gravity is 3.711m/s2, and on the moon, gravity is 1.622m/s2 (5).  These significant 
decreases in gravity lead to observable impairment in immune function for a 
number of species. Drosophila melanogaster, the common fruit fly, showed a 
complete inability to activate Toll-mediated responses to fungal infections. The 
stress of microgravity on the body resulted in a faulty transcriptional response. 
Interestingly, hypergravity conditions, where the force of gravity was higher than 
experienced on earth, actually improved the signaling strength of Toll-responses, 
resulting in a faster clearing of the fungal infection6.  
 
In mice models, a number of immune changes have been observed. 
Lymphocyte proliferation is decreased due to a downregulation of T-cell activation 
markers CD25, CD69, and CD71. Decreased lymphocyte function and proliferation, 
especially for CD4 T-cells, occurred in a time-dependent manner with exposure to 
microgravity conditions7. Microgravity causes a significant unloading of mammalian 
tissues, which decreases tissue growth and regeneration. As a result, mice showed 
decreased hematopoiesis due to down-regulation of gene-expression markers for 
early mesenchymal and hematopoietic differentiation by at least two-fold. Cultures 
of bone marrow cells after microgravity conditions showed increase of 
mesenchymal differentiation to mineralized bone nodules, whereas hemotopoietic 
differentiation primarily resulted in osteoclasts. This indicates an increase of 
undifferentiated progenitor cells after microgravity8.  Mice also show a decrease in 
lymphoid organ size relative to their body mass, with a 13-day spaceflight showing a 
significant decrease in spleen size. Thymus size was not significantly affected, but an 
increase in DNA fragmentation in the thymus was observed. T-cell and cancer gene 
expression markers were highly altered, with 30 out of 84 T-cell genes altered, and 
15 out of 84 cancer related genes altered2. This evidence suggests that there could 
be an increased risk of infection and cancer development associated with 
spaceflight. IFNγ production is of particular importance, as it is the first response to 
viral infections. Rodents showed a decrease in IFNγ production in response to T-cell 
mitogen ConA9. The decrease in IFNγ present in mice causes Swiss/Webster mice 
that are normally immune to the D variant of encephalomyocarditis to become 
unusually susceptible in microgravity conditions10.  
A further investigation of rodent models also indicated an overproduction of 
cytokines IL-6 and IL-10, and a decrease in TNFα in microgravity conditions11. 
Humans also show an impaired immune response during microgravity conditions 
experienced during spaceflight.   
 Astronauts show decreased functionality of their monocytes, with reduced 
ability to engulf E. coli, induce oxidative burst or degranulate. In addition, responses 
to gram-negative LPS endotoxins have decreased responsiveness12. These 
alterations in immunity are likely due to decreased expression of CD14 and 
increased expression of TLR4, due to LPS responsiveness depending on the 
association of the CD14-TLR4 myeloid differentiation protein 2 complex1. 
 Cytotoxicity of non-MHC-restricted killer cells was found to be depressed in 
spaceflight as well, with a 40% decrease in lytic activity after landing13. Cytokine 
expression changes have also been observed in astronauts, suggesting further 
indication of decreased natural immune response. Astronauts returning from a 7-
day spaceflight showed low NK cell activity and decreased IFN secretion, which 
would reduce the ability to respond to viral infections14. 
 The study of microgravity conditions on immune function became an 
especially prevalent topic when NASA observed a higher re-emergence of latent 
viruses in astronauts on short-duration space flights of 12 to 16 days. Astronauts 
showed increased re-emergence of Epstein-Barr virus, cytomegalovirus, herpes 
simplex I, and varicella virus3.  
 
NASA conducted further studies to investigate the alarming immune deficiencies in 
astronauts with simulated microgravity experiments. Research participants were 
found to have a decrease in activation of CD8+, CD69+, and virus-specific T-cells for 
both CMV and EBV4.  
 Research on immune function in microgravity conditions is highly relevant 
due to NASA’s plans to send humans to Mars by mid 2030s—this mission would be a 
duration of a minimum of 520 days15. Additionally, bacteria actually survive better 
in microgravity conditions, leaving humans at an even greater risk for infections. 
Bacteria are found to proliferate faster, improve gene expression and pathogenesis, 
and require higher doses of antibiotics to kill. The increased radiation in space also 
subjects bacteria to higher levels of mutations, which could lead to increased 
virulence1. Spaceflight also includes inherent risks that could increase susceptibility 
to infections, such as the emotional stress due to confinement or fear of failure.  Air, 
food, water, and waste are all recycled on board the space crafts, and the 
confinement of the passengers has been shown to increases in the transfer of 
microorganisms16, 17. The role of gravity on immune cells needs to be established 
before humans are sent on space missions lasting such an exorbitant amount of 
time, especially considering the evidence of decreased immune function in short-
duration spaceflights. Further research could definitively establish a connection 
between mechanical unloading of tissues negatively impacting hematopoiesis, 
cytokine production, and adaptive and innate immune responses.  
 
Despite the compelling research suggesting significant immune impairment in 
microgravity conditions, gaps in scientific knowledge exist on the adaptive immune 
response to specific viral infections in microgravity conditions. This research will 
investigate the hypothesis that adaptive immune responses will be deficient in 
microgravity conditions when exposed to viral infection. It is suspected that mice 
subjected to microgravity conditions will show a lower antibody response of IFNγ 




Aim 1: Eliminate possibility of extraneous factors associated with spaceflight 
besides microgravity leading to evidence of decreased immune function. 
 Studies on microgravity conditions can be simulated due to the excessive 
expense of sending research subjects and participants to space. Head-down bed rest 
(HDBR) has been established as a sufficient method of simulating microgravity 
conditions3. It involves being placed at a -6 degree angle with the head down, 
restrained at the chest and ankles (see Figure 1). This method can be used on a 
variety of experimental models, including mice.  
 Figure 1: Visual representation of head down bed rest conditions to simulate 
microgravity conditions.  
 
This method of establishing microgravity conditions rather than sending the 
research subjects to space will ensure the results obtained are not due to other 
factors, such as increased levels of radiation, stress levels, confinement, or improved 
microorganism proliferation. 
 
Aim 2: Observe if T-Cell functionality is impaired in microgravity conditions, 
and determine the effect of microgravity on adaptive immune responses to 
viral infection. 
 Lymphocytic choriomeningitis virus (LCMV) is a prominent model for 
investigating the immune system’s response to viral infection18. LCMV’s natural host 
is a mouse, but it can also infect a wide range of animals, including humans. The 
Armstrong strain of LCMV, which will be used for this experimental design, was first 
isolated from a monkey in the 1930s. 
 It is referred to as the neurotropic strain due to its high levels of replication in the 
viscera, which clonally exhausts T cells. This prevents T-cell dependent meningitis 
and encephalitis from occurring, and results in an acute infection18. LCMV is a 
Biohazard Safety Level 2 (BSL-2) pathogen. 
 The LCMV pathogen will be injected into research subjects, and their immune 
responses will be studied using plaque assays, intracellular cytokine staining, 
tetramer staining, flow cytometry, and ELISAs. Results will be compared to mice in a 
control setting. 
Experimental Design: 
 A total of 30 BALB/c mice between 8 and 10 weeks of age will be obtained 
from Jackson Laboratories for this experiment. The mice will be kept following 
Arizona State University and IUPAC regulations. Mice will acclimate for a week in 
normal conditions (no microgravity simulation) in groups of five in HEPA-filter 
caged racks. Mice will be provided water ad libitum, and food in a quantity of one 
lab block per day distributed at the same time each evening. Biosafety Level 2 
precautions and Class II biosafety cabinets will be used at all times.  
 After 1 week, 20 mice will be restrained in the HDBR position. Mice will be 
placed prone on the HDBR block at -6 degrees to allow for easier feeding. 10 mice 
will be placed prone on a flat surface to serve as a positive control. 
Viral stocks will be prepared by performing a serial dilution of the LCMV stock 
solution from 10-3 to 10-9.  
Dilutions will be used to infect cell VERO cell monolayers and to determine viral 
titer19. Ten of the mice will be injected with 2x105 PFU of LCMV intraperitoneally, 
following protocol from Guidotti et. al20. Ten mice in HDBR condition will not be 




LCMV Infection No LCMV Infection Type of Control 
10 Mice HDBR X  n/a 
10 Mice HDBR   X Negative 
10 Mice No HDBR X  Positive 
Figure 2: Indicates experimental groups involved in research design. 10 mice in 
HDBR with LCMV exposure are subjected to both experimental variables. 10 mice in 
HDBR conditions with no LCMV infection serve as a negative control, as no evidence 
of immune cell deficiencies specific to LCMV should be observed. 10 mice with no 
HDBR and exposure to LCMV are a positive control group, and will be compared to 
the mice in HDBR to quantify deficiencies in immune response to viral infection.  
At three, eight, and thirty days time post-infection, mice from each 
experimental group will have their blood or splenocytes analyzed. Experimental 
design has been adapted from the protocol established in the Experimental 
Immunology lab manual for the purposes of this research19. 
Three days post-infection, a sample of blood will be obtained from 5 mice 
from each experimental condition. The serum will be used to perform a plaque 
assay to determine if the LCMV virus is present in cells. The plaques will quantitate 
the amount of virus present in the cells.  
 Eight days post-infection, 5 mice from each experimental condition will be 
euthanized and sacrificed. A sample of their splenocytes will be obtained, and 
tetramer staining, intracellular cytokine staining, and flow cytometry will be used to 
analyze the percentage of virus specific T-cells and the number of CD8+ and CD4+ T 
cells producing IFNγ and TNF.  
To quantify number of virus specific T-cells, 1x106 splenocytes from each 
experimental condition will be centrifuged for 1 minute at 8000 rpm. The 
supernatant will be decanted, and cells will be suspended in an antibody stain in 
FACS buffer in the following dilutions: anti-CD8 (eflouro450): 1/20, anti-CD4 
(Percp-Cy5.5): 1/20, GP33 Tetramer (FITC): 1/10, and Anti-CD44 (PE): 1/10. Cells 
will be incubated for 30 minutes in 4° C in the dark. Cells will be centrifuged for 1 
minute at 8000 rpm again, washed with FACS buffer twice, and resuspended in 
200μL PFA buffer.  
To determine the number of CD8+ and CD4+ T cells producing IFNγ and TNF, 
1x106 cells from each experimental group will be pipetted separately into 2 wells of 
a 96-well plate (6 wells total). Peptide dilutions with viral peptide epitope and 
Brefeldin A will be prepared in 10% FCS-RPMI+golgiplug to a final concentration of 
2μg/mL each.  
50μL of peptide will be added to wells that contain infected splenocytes. 50μL of 
10% FCS-RPMI+golgiplug will be added to three empty wells, and 50μL of 
PMA/lonomycin will be added to three empty wells. Plates will be incubated for 6 
hours at 37°C. Plate will be centrifuged at 1300 rpm for 2.5 minutes. Supernatant 
will be decanted, and 100μL of cell surface stain in the following dilutions in FACS 
buffer will be added to each well: Anti-CD8 (eflouro450): 1/20, Anti-CD4 (Percp-
Cy5.5): 1/20. Plate will incubate at room temperature for 15 minutes in the dark, 
and be centrifuged for 2.5 minutes at 1300 rpm. Plate will be washed twice with 
FACS buffer, and 100μL of Perm/Fix solution will be added to each well. Plate will 
incubate for 20 minutes in the dark at 4°C. Plate will be washed twice with 
Perm/Wash buffer. 100μL intracellular stain in Perm/Wash buffer will be prepared 
in the following dilutions: Anti-TNF (FITC): 1/20, Anti-IFNγ (PE): 1/20. Plate will be 
incubated at room temperature for 15 minutes, then washed twice with Perm/Wash 
buffer, and finally resuspended in 200μL FACS buffer. Samples for both tetramer 
staining and intracellular cytokine staining will be run on an LSR Fortessa Flow 
Cytometer, and analyzed using Flowing 2.5.1 software.  
Thirty days post-infection, an ELISA will be used to calculate the concentration 
of cytokines IFNγ and TNF in each experimental condition. The remaining mice (5 from 
each experimental group) will be sacrificed, and their splenocytes will be sampled. 
Protocol from the Experimental Immunology lab manual will be followed in order to 
prepare ELISA plate, with the exception of LCMV-infected supernatant being used in 
place of Poly(I:C) stimulated cell supernatant.  
Unstimulated cells will be obtained from the HDBR mice with no LCMV exposure. 
Absorbance of the ELISA plate will be determined at 450 nm using a microplate 
reader19. 
Anticipated Outcomes 
 Based on previous research on the effect of microgravity on immune 
responses, the anticipated result from this experiment is that the hypothesis will be 
supported, and mice in the HDBR condition infected with LCMV will show a lower 
antibody response at 30 days than mice infected with LCMV in the control group. 
This would imply that the microgravity conditions negatively impacted the mice’s T-
cell responses, and the results from previous studies are indeed a result of 
microgravity, rather than extraneous factors associated with spaceflight. Other 
results that could be obtained could be that the mice in the HDBR condition actually 
show a better immune response to viral infections than mice in the control group. 
This seems highly unlikely based on previous findings, but if this result was 
obtained, further research could investigate the use of HDBR as a supplement to 
treating viral infections. Another possible result could be that the HDBR infected 
mice show no significant differences in antibody response at 30 days. If this data is 
obtained, an assumption could be made that other factors besides microgravity 
conditions alter the immune system’s ability to resist pathogens. One possibility 
could be that the literature showing decreased immune function during spaceflight 
is a result of genetic mutations occurring due to exposure to increased radiation 
than experienced on Earth.  
Another possibility could be that the cramped and confined positions astronauts 
face on small space shuttles is decreasing their immune response due to increased 
microorganism transfer. High stress levels associated with space flight could also 
impair the immune system. It has already been established that an increase in the 
level of cortisol, a hormone released when humans are under psychological stress, is 
found to decrease immune function and ability for wounds to heal21. Furthermore, 
the ability for bacteria to proliferate better in space could be what puts astronauts at 
highest risk, rather than the decreased immune function. Other explanations for the 
hypothesis not being supported could be due to microgravity conditions only 
negatively impacting innate immunity or responses to bacterial pathogens. Most of 
the research established on microgravity’s effect on the immune system involves 
innate responses to bacterial pathogens, and investigating the adaptive immune 
response to viral infection is a new scientific approach. Therefore, the results of the 
proposed experimental design would contribute new and pertinent information on 
the function of the adaptive immune system in microgravity conditions, especially in 
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